Component

Midazolam

Midazolam. Species, exposure and limitations are retained in each linked claim.

3 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

Read recorded mechanisms Open recursive mind map

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

Where it participates (unsigned role)

  1. No meaningful overall midazolam pharmacokinetic change was found.

    Curcuminoid-piperine preparation, study-specific → Plasma midazolam exposure source_derived_draftungraded
    Experimental context and source evidence
    evidence_span
    {"source_cache": "artifacts/curcumin-research/22725836.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "255db8a54957c442fe6fca1d21aafe393e3a5506bec7330b49e1bb6f85d86127", "start_char": 0, "end_char": 1977, "text_sha256": "255db8a54957c442fe6fca1d21aafe393e3a5506bec7330b49e1bb6f85d86127"}
    experimental_model
    Randomized six-way crossover in eight healthy volunteers
    exposure
    4 g curcuminoids plus 24 mg piperine, four doses over two days before each probe drug
    limitations
    Short regimen and small sample. A null result for these probes does not establish no interactions with all medicines or preparations.
    nutrient_topic
    Curcumin research collection; topical membership is not evidence of a direct dietary effect. · Curcumin
    organism
    Homo sapiens
    plain_language
    The CYP3A probe did not show the expected major exposure change.
    primary_references
    [curcumin-p22725836] Effect of a herbal extract containing curcumin and piperine on midazolam, flurbiprofen and paracetamol (acetaminophen) pharmacokinetics in healthy volunteers. (2013). https://pubmed.ncbi.nlm.nih.gov/22725836/ DOI: 10.1111/j.1365-2125.2012.04364.x
    tissue_or_cell_type
    Drug pharmacokinetics

    Curcumin: metabolism, signaling and nutrient connections (2026-09-17) · lines 918–929

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Randomized six-way crossover in eight healthy volunteers · source_derived_draft · unverified_draft

    ### curcumin-midazolam-null No meaningful overall midazolam pharmacokinetic change was found. Condition category: normal nutrient_topic: Curcumin research collection; topical membership is not evidence of a direct dietary effect. plain_language: The CYP3A probe did not show the expected major exposure change. organism: Homo sapiens tissue_or_cell_type: Drug pharmacokinetics experimental_model: Randomized six-way crossover in eight healthy volunteers limitations: Short regimen and small sample. A null result for these probes does not establish no interactions with all medicines or preparations. exposure: 4 g curcuminoids plus 24 mg piperine, four doses over two days before each probe drug evidence_span: {"source_cache": "artifacts/curcumin-research/22725836.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "255db8a54957c442fe6fca1d21aafe393e3a5506bec7330b49e1bb6f85d86127", "start_char": 0, "end_char": 1977, "text_sha256": "255db8a54957c442fe6fca1d21aafe393e3a5506bec7330b49e1bb6f85d86127"} [curcumin-p22725836] Effect of a herbal extract containing curcumin and piperine on midazolam, flurbiprofen and paracetamol (acetaminophen) pharmacokinetics in healthy volunteers. (2013). https://pubmed.ncbi.nlm.nih.gov/22725836/ DOI: 10.1111/j.1365-2125.2012.04364.x
    Complete structured claim and evidence

  2. Repeated berberine inhibited CYP3A4 phenotypic activity, with midazolam oral clearance reduced by 27%.

    Berberine → CYP3A4 activity measured by probe-drug phenotyping source_derived_draftungraded
    Experimental context and source evidence
    evidence_span
    {"source_cache": "artifacts/berberine-research/21870106.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "12e465c3c0a8ce995697a6fb9bf77c079e38b413e82c8b4f2a82e45a3dbf8ae5", "start_char": 0, "end_char": 1817, "text_sha256": "12e465c3c0a8ce995697a6fb9bf77c079e38b413e82c8b4f2a82e45a3dbf8ae5"}
    experimental_model
    Two-phase randomized crossover enzyme-phenotyping study
    exposure
    Berberine 300 mg three times daily for 14 days versus placebo
    limitations
    Small short-term study. Probe metabolic ratios are not percentage inhibition of every substrate. No universal dose-adjustment rule; no statistically significant effect is not equivalence.
    nutrient_topic
    Berberine research collection; topical membership is not evidence of a direct dietary effect. · Berberine
    organism
    Healthy human male volunteers; 17 completed
    plain_language
    Drug clearance was measured, rather than inferred from gene expression.
    primary_references
    [berberine-p21870106] Repeated administration of berberine inhibits cytochromes P450 in humans. (2012). https://pubmed.ncbi.nlm.nih.gov/21870106/ DOI: 10.1007/s00228-011-1108-2
    tissue_or_cell_type
    Oral probe pharmacokinetics and urinary metabolite ratios

    Berberine: metabolism, nutrient connections and drug interactions (2026-09-17) · lines 662–673

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Two-phase randomized crossover enzyme-phenotyping study · source_derived_draft · unverified_draft

    ### berberine-human-cyp-3a4 Repeated berberine inhibited CYP3A4 phenotypic activity, with midazolam oral clearance reduced by 27%. Condition category: normal nutrient_topic: Berberine research collection; topical membership is not evidence of a direct dietary effect. plain_language: Drug clearance was measured, rather than inferred from gene expression. organism: Healthy human male volunteers; 17 completed tissue_or_cell_type: Oral probe pharmacokinetics and urinary metabolite ratios experimental_model: Two-phase randomized crossover enzyme-phenotyping study limitations: Small short-term study. Probe metabolic ratios are not percentage inhibition of every substrate. No universal dose-adjustment rule; no statistically significant effect is not equivalence. exposure: Berberine 300 mg three times daily for 14 days versus placebo evidence_span: {"source_cache": "artifacts/berberine-research/21870106.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "12e465c3c0a8ce995697a6fb9bf77c079e38b413e82c8b4f2a82e45a3dbf8ae5", "start_char": 0, "end_char": 1817, "text_sha256": "12e465c3c0a8ce995697a6fb9bf77c079e38b413e82c8b4f2a82e45a3dbf8ae5"} [berberine-p21870106] Repeated administration of berberine inhibits cytochromes P450 in humans. (2012). https://pubmed.ncbi.nlm.nih.gov/21870106/ DOI: 10.1007/s00228-011-1108-2
    Complete structured claim and evidence

  3. Midazolam AUC to infinity increased approximately 40% and Cmax 38% after repeated berberine.

    Berberine → Plasma midazolam exposure source_derived_draftungraded
    Experimental context and source evidence
    evidence_span
    {"source_cache": "artifacts/berberine-research/21870106.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "12e465c3c0a8ce995697a6fb9bf77c079e38b413e82c8b4f2a82e45a3dbf8ae5", "start_char": 0, "end_char": 1817, "text_sha256": "12e465c3c0a8ce995697a6fb9bf77c079e38b413e82c8b4f2a82e45a3dbf8ae5"}
    experimental_model
    Two-phase randomized crossover enzyme-phenotyping study
    exposure
    Berberine 300 mg three times daily for 14 days versus placebo
    limitations
    Small short-term study. Probe metabolic ratios are not percentage inhibition of every substrate. No universal dose-adjustment rule; no statistically significant effect is not equivalence.
    nutrient_topic
    Berberine research collection; topical membership is not evidence of a direct dietary effect. · Berberine
    organism
    Healthy human male volunteers; 17 completed
    plain_language
    One actual medicine had greater systemic exposure in this controlled study.
    primary_references
    [berberine-p21870106] Repeated administration of berberine inhibits cytochromes P450 in humans. (2012). https://pubmed.ncbi.nlm.nih.gov/21870106/ DOI: 10.1007/s00228-011-1108-2
    tissue_or_cell_type
    Oral probe pharmacokinetics and urinary metabolite ratios

    Berberine: metabolism, nutrient connections and drug interactions (2026-09-17) · lines 701–712

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Two-phase randomized crossover enzyme-phenotyping study · source_derived_draft · unverified_draft

    ### berberine-midazolam-auc Midazolam AUC to infinity increased approximately 40% and Cmax 38% after repeated berberine. Condition category: normal nutrient_topic: Berberine research collection; topical membership is not evidence of a direct dietary effect. plain_language: One actual medicine had greater systemic exposure in this controlled study. organism: Healthy human male volunteers; 17 completed tissue_or_cell_type: Oral probe pharmacokinetics and urinary metabolite ratios experimental_model: Two-phase randomized crossover enzyme-phenotyping study limitations: Small short-term study. Probe metabolic ratios are not percentage inhibition of every substrate. No universal dose-adjustment rule; no statistically significant effect is not equivalence. exposure: Berberine 300 mg three times daily for 14 days versus placebo evidence_span: {"source_cache": "artifacts/berberine-research/21870106.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "12e465c3c0a8ce995697a6fb9bf77c079e38b413e82c8b4f2a82e45a3dbf8ae5", "start_char": 0, "end_char": 1817, "text_sha256": "12e465c3c0a8ce995697a6fb9bf77c079e38b413e82c8b4f2a82e45a3dbf8ae5"} [berberine-p21870106] Repeated administration of berberine inhibits cytochromes P450 in humans. (2012). https://pubmed.ncbi.nlm.nih.gov/21870106/ DOI: 10.1007/s00228-011-1108-2
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

    Evidence, AI assistance and curation standards